Cellular immunity to the Her-2/neu protooncogene.

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Human epidermal growth factor receptor 2 (HER-2) is a glycoprotein overexpressed in various cancers, including breast, ovarian, gastric, and colorectal carcinomas.
• HER-2 overexpression is linked to malignant transformation and serves as a marker of poor prognosis.
• Its selective expression on cancer cells makes HER-2 an attractive target for immunotherapy.

Purpose of the Study:

• To review the role of HER-2 in cancer and its potential as an immunotherapy target.
• To discuss current antibody and T-cell based immunotherapies for HER-2 positive tumors.
• To explore novel vaccination strategies for enhancing T-cell mediated anti-HER-2 responses.

Main Methods:

• Review of existing literature on HER-2 immunotherapy.
• Analysis of clinical trial data for Herceptin (trastuzumab).
• Examination of preclinical and clinical studies on T-cell based vaccination strategies.

Main Results:

• Herceptin (trastuzumab) shows efficacy as adjuvant therapy for HER-2 positive breast and ovarian cancers, but response rates are limited and resistance develops.
• Naturally occurring HER-2 reactive T cells and antibodies confirm its immunogenicity.
• Vaccination strategies are being developed to elicit robust T-cell responses against HER-2.

Conclusions:

• While Herceptin is a valuable tool, its limitations necessitate alternative or complementary approaches.
• T-cell mediated immunotherapies, particularly through vaccination, hold promise for overcoming resistance and improving outcomes in HER-2 positive cancers.
• Further research into HER-2 immunotherapy mechanisms and evasion strategies is crucial.